ClinicaliQ Trial Snapshot
- Durvalumab and Tremelimumab for Pediatric Malignancies — Active Not Recruiting • Phase I / Phase II • Oncology • NCT03837899.
- Study testing safe doses of two immunotherapy drugs in children with advanced cancers, then checking if they work.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined. Conditions: Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies Interventions: Durvalumab / Tremelimumab Combination Therapy Lead Sponsor: AstraZeneca Planned Enrollment: 50 participants